<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0810246015
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Sitavic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SITAGLIPTIN PHOSPHATE,METFORMIN HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50,850
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        56
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        88
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10BD07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Sitavic&trade; contains two different medicines called sitagliptin and metformin.<br />&bull; sitagliptin belongs to a class of medicines called DPP-4 inhibitors<br />(dipeptidyl peptidase-4 inhibitors)<br />&bull; metformin belongs to a class of medicines called biguanides.<br />They work together to control blood sugar levels in adult patients with a<br />form of diabetes called &lsquo;type 2 diabetes mellitus&rsquo;. This medicine helps to<br />increase the levels of insulin produced after a meal and lowers the amount<br />of sugar made by your body.<br />Along with diet and exercise, this medicine helps lower your blood sugar.<br />This medicine can be used alone or with certain other medicines for diabetes<br />(insulin, sulphonylureas, or glitazones).<br />What is type 2 diabetes?<br />Type 2 diabetes is a condition in which your body does not make enough<br />insulin, and the insulin that your body produces does not work as well as it<br />should. Your body can also make too much sugar.<br />When this happens, sugar (glucose) builds up in the blood. This can lead to<br />serious medical problems like heart disease, kidney disease, blindness, and<br />amputation.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Sitavic&trade;:<br />- if you are allergic to sitagliptin or metformin or any of the other ingredients<br />of this medicine (listed in section 6).<br />- if you have severely reduced kidney function<br />- if you have uncontrolled diabetes, with e.g. severe hyperglycaemia<br />(high blood glucose), nausea, vomiting, diarrhoea, rapid weight loss, lactic<br />acidosis (see &ldquo;Risk of lactic acidosis&rdquo; below) or ketoacidosis. Ketoacidosis is<br />a condition in which substances called &lsquo;ketone bodies&rsquo; accumulate in the<br />blood and which can lead to diabetic pre-coma. Symptoms include stomach<br />pain, fast and deep breathing, sleepiness or your breath developing an<br />unusual fruity smell.<br />- if you have a severe infection or are dehydrated<br />- if you are going to have an X-ray where you will be injected with a dye.<br />You will need to stop taking Sitavic&trade; at the time of the X-ray and for 2 or<br />more days after as directed by your doctor, depending on how your kidneys<br />are working<br />- if you have recently had a heart attack or have severe circulatory problems,<br />such as &lsquo;shock&rsquo; or breathing difficulties<br />- if you have liver problems<br />- if you drink alcohol to excess (either every day or only from time to time)<br />- if you are breast-feeding<br />Do not take Sitavic&trade; if any of the above apply to you and talk with your<br />doctor about other ways of managing your diabetes. If you are not sure, talk<br />to your doctor, pharmacist or nurse before taking Sitavic&trade;.<br />Warnings and precautions<br />Cases of inflammation of the pancreas (pancreatitis) have been reported in<br />patients receiving Sitavic&trade; (see section 4).<br />If you encounter blistering of the skin it may be a sign for a condition called<br />bullous pemphigoid. Your doctor may ask you to stop Sitavic&trade;.<br />Risk of lactic acidosis<br />Sitavic&trade; may cause a very rare, but very serious side effect called lactic<br />acidosis, particularly if your kidneys are not working properly. The risk of<br />developing lactic acidosis is also increased with uncontrolled diabetes,<br />serious infections, prolonged fasting or alcohol intake, dehydration<br />(see further information below), liver problems and any medical conditions<br />in which a part of the body has a reduced supply of oxygen (such as acute<br />severe heart disease).<br />If any of the above apply to you, talk to your doctor for further instructions.<br />Stop taking Sitavic&trade; for a short time if you have a condition that may<br />be associated with dehydration (significant loss of body fluids) such as<br />severe vomiting, diarrhoea, fever, exposure to heat or if you drink less fluid<br />than normal. Talk to your doctor for further instructions.<br />Stop taking Sitavic&trade; and contact a doctor or the nearest hospital<br />immediately if you experience some of the symptoms of lactic acidosis,<br />as this condition may lead to coma.<br />Symptoms of lactic acidosis include:<br />- vomiting<br />- stomach ache (abdominal pain)<br />- muscle cramps<br />- a general feeling of not being well with severe tiredness<br />- difficulty in breathing<br />- reduced body temperature and heartbeat<br />Lactic acidosis is a medical emergency and must be treated in a hospital.<br />Talk to your doctor or pharmacist before taking Sitavic&trade;:<br />- if you have or have had a disease of the pancreas (such as pancreatitis)<br />- if you have or have had gallstones, alcohol dependence or very high levels<br />of triglycerides (a form of fat) in your blood. These medical conditions can<br />increase your chance of getting pancreatitis (see section 4)<br />- if you have type 1 diabetes. This is sometimes called insulin-dependent<br />diabetes<br />- if you have or have had an allergic reaction to sitagliptin, metformin, or<br />Sitavic&trade; (see section 4)<br />- if you are taking a sulphonylurea or insulin, diabetes medicines, together<br />with Sitavic&trade;, as you may experience low blood sugar levels<br />(hypoglycaemia). Your doctor may reduce the dose of your sulphonylurea or<br />insulin<br />If you need to have major surgery you must stop taking Sitavic&trade; during and<br />for some time after the procedure. Your doctor will decide when you must<br />stop and when to restart your treatment with Sitavic&trade;.<br />If you are not sure if any of the above apply to you, talk to your doctor or<br />pharmacist before taking Sitavic&trade;.<br />During treatment with Sitavic&trade;, your doctor will check your kidney<br />function at least once a year or more frequently if you are elderly and/or if<br />you have worsening kidney function.<br />Children and adolescents<br />Children and adolescents below 18 years should not use this medicine. It is<br />not known if this medicine is safe and effective when used in children and<br />adolescents under 18 years of age.<br />Other medicines and Sitavic&trade;<br />If you need to have an injection of a contrast medium that contains iodine<br />into your bloodstream, for example, in the context of an X-ray or scan, you<br />must stop taking Sitavic&trade; before or at the time of the injection. Your doctor<br />will decide when you must stop and when to restart your treatment with<br />Sitavic&trade;.<br />Tell your doctor or pharmacist if you are taking, have recently taken or might<br />take any other medicines. You may need more frequent blood glucose and<br />kidney function tests, or your doctor may need to adjust the dosage of<br />Sitavic&trade;. It is especially important to mention the following:<br />&bull; medicines (taken by mouth, inhalation, or injection) used to treat diseases<br />that involve inflammation, like asthma and arthritis (corticosteroids)<br />&bull; medicines which increase urine production (diuretics)<br />&bull; medicines used to treat pain and inflammation (NSAID and COX-2-inhibitors,<br />such as ibuprofen and celecoxib)<br />&bull; certain medicines for the treatment of high blood pressure (ACE inhibitors<br />and angiotensin II receptor antagonists)<br />&bull; specific medicines for the treatment of bronchial asthma<br />(&beta;-sympathomimetics)<br />&bull; iodinated contrast agents or alcohol-containing medicines<br />&bull; certain medicines used to treat stomach problems such as cimetidine<br />&bull; ranolazine, a medicine used to treat angina<br />&bull; dolutegravir, a medicine used to treat HIV infection<br />&bull; vandetanib, a medicine used to treat a specific type of thyroid cancer<br />(medullary thyroid cancer)<br />&bull; digoxin (to treat irregular heart beat and other heart problems). The level of<br />digoxin in your blood may need to be checked if taking with Sitavic&trade;.<br />Sitavic&trade; with alcohol<br />Avoid excessive alcohol intake while taking Sitavic&trade; since this may<br />increase the risk of lactic acidosis (see section &ldquo;Warnings and precautions&rdquo;).<br />Pregnancy and breast-feeding<br />If you are pregnant or breast-feeding, think you may be pregnant or are<br />planning to have a baby, ask your doctor or pharmacist for advice before<br />taking this medicine. You should not take this medicine during pregnancy or<br />if you are breast-feeding. See section 2, Do not take Sitavic&trade;.<br />Driving and using machines<br />This medicine has no or negligible influence on the ability to drive and use<br />machines. However, dizziness and drowsiness have been reported with<br />sitagliptin, which may affect your ability to drive or use machines.<br />Taking this medicine in combination with medicines called sulphonylureas<br />or with insulin can cause hypoglycaemia, which may affect your ability to<br />drive and use machines or work without safe foothold.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with<br />your doctor or pharmacist if you are not sure.<br />&bull; Take one tablet:<br />&bull; twice daily by mouth<br />&bull; with meals to lower your chance of an upset stomach.<br />&bull; Your doctor may need to increase your dose to control your blood sugar.<br />&bull; If you have reduced kidney function, your doctor may prescribe a lower<br />dose.</p><p>You should continue the diet recommended by your doctor during<br />treatment with this medicine and take care that your carbohydrate intake<br />is equally distributed over the day.<br />This medicine alone is unlikely to cause abnormally low blood sugar<br />(hypoglycaemia). When this medicine is used with a sulphonylurea<br />medicine or with insulin, low blood sugar can occur and your doctor<br />may reduce the dose of your sulphonylurea or insulin.<br />If you take more Sitavic&trade; than you should<br />If you take more than the prescribed dosage of this medicine, contact<br />your doctor immediately. Go to the hospital if you have symptoms of<br />lactic acidosis such as feeling cold or uncomfortable, severe nausea or<br />vomiting, stomach ache, unexplained weight loss, muscular cramps, or<br />rapid breathing (see section &ldquo;Warnings and precautions&rdquo;).<br />If you forget to take Sitavic&trade;<br />If you miss a dose, take it as soon as you remember. If you do not<br />remember until it is time for your next dose, skip the missed dose and go<br />back to your regular schedule. Do not take a double dose of this<br />medicine.<br />If you stop taking Sitavic&trade;<br />Continue to take this medicine as long as your doctor prescribes it so<br />you can continue to help control your blood sugar. You should not stop<br />taking this medicine without talking to your doctor first. If you<br />stop taking Sitavic&trade;, your blood sugar may rise again.<br />If you have any further questions on the use of this medicine, ask your<br />doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not<br />everybody gets them.<br />STOP taking Sitavic&trade; and contact a doctor immediately if you notice<br />any of the following serious side effects:<br />&bull; Severe and persistent pain in the abdomen (stomach area) which might<br />reach through to your back with or without nausea and vomiting, as<br />these could be signs of an inflamed pancreas (pancreatitis).<br />Sitavic&trade; may cause a very rare (may affect up to 1 in 10,000 people),<br />but very serious side effect called lactic acidosis (see section &ldquo;Warnings<br />and precautions&rdquo;). If this happens, you must stop taking Sitavic&trade; and<br />contact a doctor or the nearest hospital immediately, as lactic acidosis<br />may lead to coma.<br />If you have a serious allergic reaction (frequency not known), including<br />rash, hives, blisters on the skin/peeling skin and swelling of the face,<br />lips, tongue, and throat that may cause difficulty in breathing or<br />swallowing, stop taking this medicine and call your doctor right away.<br />Your doctor may prescribe a medicine to treat your allergic reaction and<br />a different medicine for your diabetes.<br />Some patients taking metformin have experienced the following side<br />effects after starting sitagliptin:<br />Common (may affect up to 1 in 10 people): low blood sugar, nausea,<br />flatulence, vomiting.<br />Uncommon (may affect up to 1 in 100 people): stomach ache,<br />diarrhoea, constipation, drowsiness.<br />Some patients have experienced diarrhoea, nausea, flatulence,<br />constipation, stomach ache or vomiting when starting the combination<br />of sitagliptin and metformin together (frequency is common).<br />Some patients have experienced the following side effects while<br />taking this medicine with a sulphonylurea such as glimepiride:<br />Very common (may affect more than 1 in 10 people): low blood sugar<br />Common: constipation.<br />Some patients have experienced the following side effects while<br />taking this medicine in combination with pioglitazone:<br />Common: swelling of the hands or legs<br />Some patients have experienced the following side effects while<br />taking this medicine in combination with insulin:<br />Very common: low blood sugar<br />Uncommon: dry mouth, headache<br />Some patients have experienced the following side effects during<br />clinical studies while taking sitagliptin alone (one of the medicines in<br />Sitavic&trade;) or during post-approval use of Sitavic&trade; or sitagliptin alone<br />or with other diabetes medicines:<br />Common: low blood sugar, headache, upper respiratory infection, stuffy<br />or runny nose and sore throat, osteoarthritis, arm or leg pain.<br />Uncommon: dizziness, constipation, itching<br />Rare: reduced number of platelets<br />Frequency not known: kidney problems (sometimes requiring dialysis),<br />vomiting, joint pain, muscle pain, back pain, interstitial lung disease,<br />bullous pemphigoid (a type of skin blister)<br />Some patients have experienced the following side effects while<br />taking metformin alone:<br />Very common: nausea, vomiting, diarrhoea, stomach ache and loss of<br />appetite. These symptoms may happen when you start taking metformin<br />and usually go away<br />Common: a metallic taste<br />Very rare: decreased vitamin B12 levels, hepatitis (a problem with your<br />liver), hives, redness of the skin (rash) or itching.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor, pharmacist or nurse. This<br />includes any possible side effects not listed in this leaflet. By reporting<br />side effects, you can help provide more information on the safety of this<br />medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the<br />blister and the carton after &#39;EXP&#39;.<br />Do not store above 30 oC.<br />Do not throw away any medicines via wastewater or household waste.<br />Ask your pharmacist how to throw away medicines you no longer use.<br />These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Sitavic&trade; contains:<br />- The active substances are sitagliptin and metformin:<br />Sitavic&trade; 50 mg/ 850 mg: Each Film Coated Tablet contains 50 mg of<br />Sitagliptin (eq. to 64.25 mg of Sitagliptin Phosphate Monohydrate) and<br />850 mg of Metformin Hydrochloride.<br />Sitavic&trade; 50 mg/ 1000 mg: Each Film Coated Tablet contains 50 mg of<br />Sitagliptin (eq. to 64.25 mg of Sitagliptin Phosphate Monohydrate) and<br />1000 mg of Metformin Hydrochloride<br />- The other ingredients are:<br />Polyvinylpyrrolidone, Sodium Lauryl sulphate, Microcrystalline<br />cellulose, Sodium Stearyl Fumarate, Polyvinyl Alcohol, Polyethylene<br />Glycol, Talc, Titanium dioxide, Iron Oxide Red and Black Iron Oxide.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Sitavic™ looks like and contents of the pack:
Sitavic™ 50 mg/ 850 mg: Pink colored, capsule shaped film coated
tablets debossed with "JP" on one side and “206” on the other side.
Sitavic™ 50 mg/ 1000 mg: Red colored, capsule shaped film coated
tablets debossed with "JP" on one side and “207” on the other side.
Sitavic™ 50 mg/ 850 mg tablets are available in a box of 8 blisters,
7 tablets per each blister.
Sitavic™ 50 mg/ 1000 mg tablets are available in a box of 8 blisters,
7 tablets per each blister.
Not all packs may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder and Manufacturer<br />Jamjoom Pharmaceuticals Factory Co.,<br />Jeddah, Makkah Region, Saudi Arabia.<br />Tel: +966-12-6081111.<br />Fax: +966-12-6081222.<br />Website: www.jamjoompharma.com<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222,<br />Ext: 2317-2356-2340.<br />o Reporting hotline: 19999<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last reviewed at 09/2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="ltr"><br />&trade; یحتوي سیتافیك على مادتین فعالیتین مختلفتین یُعرفوا باسم سیتاجلبتین و میتفورمین.<br />&bull; تنتمي مادة سیتاجلبتین إلى مجموعة من الأدویة تُعرف باسم مثبطات ثنائي ببتیدیل ببتیداز- ٤<br />.(DPP-4)<br />&bull; تنتمي مادة میتفورمین إلى مجموعة من الأدویة تُعرف باسم &quot;بیجوانیدز&quot;. تعمل كلتا المادتین<br />الفعالتین على ضبط مستویات السكر في الدم في المرضى من البالغین الذین یعانون من أحد أنواع<br />أمراض السكري المعروف باسم &quot;مرض السُّكَّري من النوع ۲&quot;. یُساعد ھذا الدَّواء في تحسین<br />مستویات الأنسولین وتأثیره بعد تناوُل الوجبات، ویقلل من كمیة السكر الذي ینتجھ الجسم. یُساعد<br />ھذا الدَّواء، مع اتباع نظام غذائي وممارسة الریاضة في تقلیل مستوى السكر في الدم. ویُمكن<br />استخدام ھذا الدواء بمفرده أو بالتزامن مع بعض الأدویة الأخرى المضادة لمرض السكري مثل<br />(أنسولین، سلفونیل یوریا أو جلیتازونز).<br />ما ھو مرض السكري من النوع الثاني؟<br />یُعد مرض السكري من النوع ۲ حالة مرضیة یعجز فیھا الجسم عن إفراز ما یكفي من الأنسولین<br />أو أن یكون الأنسولین الذي یفرزه الجسم لا یعمل كما یجب. كما یمكن للجسم أیضًا أن یُفرز كمیة<br />زائدة عن الحاجة من السكر. وعند حدوث ذلك، یتراكم السكر (الجلوكوز) في الدَّم. مما یُؤدي إلى<br />حدوث مشاكل طبیة خطیرة مثل أمراض القلب والكُلى وفقدان البصر والبتر &quot;ھو إزالة أحد<br />أطراف الجسم بعد إصابة جسدیة أو جراحة&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr">یحظر تناول سیتافیك في الحالات التالیة:&nbsp;<br />&bull; إذا كنت تعاني من حساسیة تجاه سیتاجلبتین أو میتفورمین أو تجاه أي مكون من المكونات<br />.( الأخرى الداخلة بتركیب ھذا الدَّواء (المدرجة في القسم رقم ٦<br />&bull; إذا كنت تعاني من قصور شدید في وظائف الكلى.<br />&bull; إذا كُنت مصابًا بمرض السكري غیر المتحكم فیھ مع الأعراض التالیة على سبیل المثال: فرط<br />سكر الدَّم الحاد (ارتفاع نسبة الجلوكوز في الدم)، غثیان، قيء، إسھال، فقدان الوزن السریع،<br />الحُماض اللاكتیكي (انظر الجزء الخاص بمخاطر &quot;الحماض اللاكتیكي أدناه&quot;) أو الحُماض<br />الكیتوني السكري. یعتبر الحُماض الكیتوني السكري ھو حالة مرضیة تتراكم فیھا المواد المعروفة<br />باسم &quot;الأجسام الكیتونیة&quot; في الدم ویمكن أن تؤدي إلى الدخول في مقدمات غیبوبة سكر. وتشمل<br />الأعراض آلام بالمعدة، سرعة أو عمق التنفس، شعور بالنعاس أو انبعاث رائحة غیر طبیعیة تشبھ<br />رائحة الفاكھة من الفم.<br />&bull; إذا كنت تعاني من عدوى شدیدة أو جفاف.<br />&nbsp;إذا كنت ستخضع للحقن بمادة صبغیة لإجراء الأشعة السینیة. ینبغي إیقاف تناوُل سیتافیك<br />أثناء إجراء الأشعة السینیة ولمدة یومین أو أكثر بعد إجرائھا وفقًا لتوجیھات الطبیب المعالج لك<br />وبناءً على عمل وظائف الكُلى.<br />&bull; إذا كنت قد أُصبت مؤخرًا بنوبة قلبیة أو إذا كنت تعاني من مشاكل حادة بالدورة الدَّمویة<br />كالصدمة أو تعاني من صعوبة التَّنفس.<br />&bull; إذا كنت تعاني من مشاكل في الكبد.<br />&bull; إذا كنت تفرط في شرب الكحولیات (سواء كان ذلك بشكل یومي أو من حین لآخر).<br />&bull; إذا كنتِ تمارسین الرضاعة الطبیعیة.<br />إذا انطبقت علیك حالة أي من الحالات المذكورة أعلاه، كما ینبغي ،&trade; یُحظر تناول سیتافیك<br />استشارة الطبیب المعالج لك لاتباع الطرق الأخرى للتحكم في مرض السكري. استشر الطبیب<br />إذا لم ،&trade; المعالج لك أو الصیدلي الخاص بك أو الممرض(ة) المتابع(ة) لحالتك قبل تناوُل سیتافیك<br />تكن متأكدًا من كیفیة التناول.<br />تحذیرات واحتیاطات:<br />تم تسجیل حدوث حالات من التھاب البنكریاس (التھابات البنكریاس) في المرضى الذین یتناولون<br />.( انظر القسم رقم ٤ ) &trade; سیتافیك<br />إذا ظھرت لدیك تقرحات في الجلد فقد تكون علامة على وجود حالة تسمى شَبیھُ الفُقَاع. قد یطلب<br />.&trade; الطبیب المعالج لك بإیقاف العلاج باستخدام سیتافیك<br />مخاطر الحُماض اللاكتیكي<br />&nbsp;قد یؤدي سیتافیك إلى حدوث مضاعفات نادرة جدًا ولكنھا شدیدة الخطورة تُسمى بالحماض &trade;<br />اللاكتیكي وبصفة خاصة إذا كانت الكلي لا تعمل بكفاءة كافیة. یزداد خطر الإصابة بالحماض<br />اللاكتیكي كنتیجة للإصابة بمرض السكري غیر المتحكم فیھ أو العدوى الشدیدة أو الصیام لفترات<br />طویلة أو تناول الكحولیات أو التعرض للجفاف (تعرف على المزید المعلومات الواردة أدناه)<br />ومشاكل بالكبد وأي حالة مرضیة تتعلق بانخفاض إمدادات الأكسجین إلى أي عضو من أعضاء<br />الجسم (مثل مرض القلب الشدید الحاد).<br />إذا انطبقت علیك أیًا حالة من الحالات المذكورة أعلاه، فیُرجى التَّحدث إلى الطبیب المعالج لك<br />للحصول على المزید من التعلیمات.<br />لفترة قصیرة إذا كنت تعاني من حالة مرضیة تتعلق بالجفاف (فقدان &trade; توقف عن تناول سیتافیك<br />سوائل الجسم بصورة كبیرة) مثل الإصابة بقيء حاد، إسھال، حمى، التعرض للحرارة أو إذا كنت<br />تشرب سوائل بمعدل أقل من المعتاد. فیُرجى التَّحدث إلى الطبیب المعالج لك للحصول على المزید<br />من التعلیمات.<br />واتصل بالطبیب المعالج لك أو اذھب إلى أقرب مستشفى لك فورًا، إذا &trade; توقف عن تناول سیتافیك<br />كنت تعاني من بعض أعراض الحماض اللاكتیكي، من المحتمل أن تؤدي ھذه الحالة إلى الإصابة<br />بغیبوبة.<br />تشمل أعراض الحماض اللاكتیكي ما یلي:<br />&bull; قيء.<br />&bull; ألم بالبطن (آلام بالمعدة).<br />&bull; تشنجات عضلیة.<br />&bull; شعور عام بالإعیاء والتعب الشدید.<br />&bull; صعوبة في التنفس.<br />&bull; انخفاض درجة جرارة الجسم ومعدل ضربات القلب.<br />الحُماض اللاكتیكي ھي حالة طبیة طارئة و ینبغي علاجھا في المستشفى.<br />:&trade; یٌرجى استشارة الطبیب المعالج لك أو الصیدلي الخاص بك قبل تناول سیتافیك<br />&bull; إذا كنت تُعاني أو قد عانیت مسبقًا من مرض البنكریاس (مثل التھاب البنكریاس).<br />&bull; إذا كنت تُعاني أو قد عانیت مسبقًا من حصى بالمرارة أو إدمان الكحولیات أو ارتفاع مُستویات<br />الدھون الثلاثیة (أحد أنواع الدھون) في الدم. یُمكِن أن تُزید ھذه الحالات الطبیة من معدل إصابتك<br />.( بالتھاب البنكریاس (انظر القسم رقم ٤<br />&bull; إذا كنت مصابًا بمرض السكري من النوع الأول. یسمى ذلك في بعض الأحیان &quot;مرض السكري<br />المعتمد على الأنسولین&quot;<br />&trade; &bull; إذا كنت تُعاني أو قد عانیت مسبقًا من حساسیة تجاه سیتاجلبتین أو میتفورمین أو سیتافیك<br />.( (انظر القسم رقم ٤<br />&bull; إذا كنت تستخدم سلفونیل یوریا أو أنسولین أو أیة أدویة أخرى لعلاج مرض السكري بالتزامن<br />فقد تعاني من انخفاض في مستوى السكر في الدم (نقص سكر الدم). قد یقوم الطبیب ،&trade; مع سیتافیك<br />المعالج لك بتقلیل جرعة سلفونیل یوریا أو أنسولین.<br />إذا كنت ستخضع لإجراء جراحة كبیرة أثناء ،&trade; ینبغي إیقاف تناول العلاج باستخدام سیتافیك<br />العملیة وبعدھا لبعض الوقت. سیقرر الطبیب المعالج لك متى ینبغي إیقاف العلاج باستخدام<br />ومتى یتم استئنافھ مرة أخرى. &trade; سیتافیك<br />إذا لم تكن متأكدًا ما إذا كان ینطبق علیك أي مما سبق أعلاه، فیُرجى التحدث إلى الطبیب المعالج<br />.&trade; لك أو الصیدلي الخاص بك قبل تناول سیتافیك<br />سیقوم الطبیب المعالج لك بفحص وظائف الكلى على الأقل مرة ،&trade; أثناء العلاج باستخدام سیتافیك<br />واحدة سنویًا أو أكثر، إذا كنت من المرضى من كبار السن و /أو إذا كنت تعاني من تدھور في<br />وظائف الكلى.<br />المرضى من الأطفال والمراھقین<br />یحظر استخدام ھذا الدَّواء من قبل المرضى من الأطفال والمراھقین الذین تقل أعمارھم عن ۱۸<br />سنة. من غیر المعروف ما إذا كان ھذا الدواء آمنًا وفعّالًا عند استخدامھ في المرضى من الأطفال<br />والمراھقین الذین تقل أعمارھم عن ۱۸ سنة.<br />&trade; تناوُل أدویة أخرى مع سیتافیك<br />إذا كنت ستخضع للحقن بمادة تباین تحتوي على الیود في مجرى الدم أثناء الفحص باستخدام<br />قبل أو أثناء وقت &trade; الأشعة السینیة أو المسح الضوئي، فیجب إیقاف العلاج باستخدام سیتافیك<br />ومتى یتعین &trade; الحقن. سیقرر الطبیب المعالج لك متى یتعین علیك إیقاف العلاج باستخدام سیتافیك<br />علیك استئنافھ مرة أخرى.<br />یُرجى إبلاغ الطبیب المُعالج لك، إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أیَّة أدویة أخرى.<br />قد تحتاج إلى إجراء فحوصات متكررة لقیاس جلوكوز الدم واختبارات وظائف الكُلى، أو قد یحتاج<br />یُعد أمرًا ھامًا للغایة أن تخبر الطبیب المعالج لك .&trade; الطبیب المعالج لك إلى تعدیل جرعة سیتافیك<br />إذا كنت تتناول أي من الأدویة التالیة:<br />&bull; الأدویة المستخدمة لعلاج الأمراض التي تشمل على حدوث التھابات مثل مرض الربو والتھابات<br />المفاصل (سواء تلك التي یتم تناولھا عن طریق الفم أو الاستنشاق أو الحقن)، مثل<br />(الكورتیكوستیرویدات).<br />&bull; الأدویة التي تزید من إدرار البول (مُدِرات البول).<br />&bull; الأدویة المستخدمة لعلاج الآلام والالتھابات (مضادات الالتھاب غیر الستیرویدیة ومثبطات<br />۲ مثل إیبوبروفین و سیلیكوكسیب). -COX<br />&bull; الأدویة المستخدمة لعلاج ارتفاع ضغط الدَّم (مُثبطات إنزیم تحویل الأنجیوتنسین وحاصرات<br />.( مستقبلات الأنجیوتنسین ۲<br />&bull; الأدویة المستخدمة في علاج حالات الربو القصبي (أدویة لھا تأثیر ودي محفز للجھاز<br />السمبثاوي من النوع بیتا).<br />&bull; عند استخدام مواد التباین المحتویة على الأیودین أو الأدویة التي تحتوي على الكحولیات.<br />&bull; بعض الأدویة المستخدمة لعلاج اضطرابات المعدة مثل (سیمیتیدین).<br />&bull; رانولازین، دواء یُستخدم لعلاج الذبحة الصدریة.<br />&bull; دولوتجرافیر، دواء یُستخدم لعلاج عدوى فیروس نقص المناعة البشریة.<br />&bull; فاندیتانیب، دواء یُستخدم لعلاج أحد أنواع سرطانات الغدة الدرقیة<br />(سرطان الغدة الدرقیة النخاعي).<br />&bull; دیجوكسین، دواء یُستخدم لعلاج ضربات القلب غیر المنتظمة واضطرابات القلب الأخرى.<br />.&trade; ینبغي إجراء فحص لمستوى دیجوكسین في الدم، إذا كنت تتناولھ بالتزامن مع سیتافیك<br />مع شرب الكحولیات &trade; استخدام سیتافیك<br />لأن ذلك قد یزید من خطر ،&trade; یجب تجنب الإفراط في شرب الكحولیات أثناء استخدام سیتافیك<br />الإصابة بالحماض اللاكتیكي (انظر قسم &quot;تحذیرات واحتیاطات&quot;).<br />الحمل والرضاعة الطبیعیة<br />إذا كنتِ حاملًا أو تمارسین الرضاعة الطبیعیة أو تعتقدین أنكِ حاملاً أو تخطِّطین لذلك، فاستشیري<br />الطبیب المعالج لكِ أو الصیدلي الخاص بكِ قبل تناوُل ھذا الدَّواء. یحظر علیكِ تناول ھذا الدواء<br />أثناء الحمل أو إذا كنتِ تمارسین الرضاعة الطبیعیة (انظري القسم رقم ۲)، یحظر تتناول<br />في الحالات التالیة &trade; سیتافیك<br />القیادة واستخدام الآلات<br />لیس لھذا الدواء أي تأثیر یُذكر في القدرة على قیادة السیارات واستخدام الآلات. ومع ذلك، تم<br />الإبلاغ عن الإصابة بدوخة ونُعاس أثناء استخدام سیتاجلبتین، مما قد یُؤثر في قدرتك على قیادة<br />السیارات أو استخدام الآلات.<br />تناوُل ھذا الدواء بالتزامن مع أدویة أخرى تُعرف باسم سلفونیل یوریا أو الأنسولین، حیث یمكن أن<br />یتسبب ذلك في نقص سكر الدَّم، والذي بدوره قد یُؤثر في قدرتك على قیادة السیارات واستخدام<br />الآلات أو العمل بتركیز تام وثبات كامل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr">تناول دائمًا ھذا الدَّواء تمامًا كما أخبرك الطبیب المعالج لك. یُرجى مراجعة الطبیب المعالج لكِ أو<br />الصیدلي الخاص بك إذا لم تكن متأكدًا من كیفیة التَّناوُل.<br />&bull; تناول قرص واحد:<br />&bull; مرتین یومیًا عن طریق الفم.<br />&bull; ینبغي تناولھ مع الوجبات للتقلیل من فرصة حدوث تھیُّج للمعدة.<br />&bull; قد یحتاج الطبیب المعالج لك إلى زیادة جرعة الدواء الخاصة بك للتحكم في تركیز السكر في<br />الدَّم.<br />&bull; إذا كنت تعاني من قصور في وظائف الكلى، فقد یصف لك الطبیب المعالج لك جرعة أقل.<br />ینبغي أن تستمر في اتباع نظامك الغذائي الذي أوصى بھ الطبیب المعالج لك أثناء فترة العلاج<br />واحرص على توزیع كمیات الكربوھیدرات الخاصة بك بصورة متساویة &trade; باستخدام سیتافیك<br />على مدار الیوم.</p><p dir="ltr">من غیر المحتمل أن یؤدي استخدام ھذا الدواء وحده إلى انخفاض السكر في الدم بشكل غیر<br />طبیعي (نقص السكر في الدم). قد یؤدي استخدام ھذا الدواء بالتزامن مع سلفونیل یوریا أو<br />الأنسولین إلى انخفاض السكر في الدم ولذلك قد یقلل الطبیب المعالج لك جرعة سلفونیل یوریا<br />أو الأنسولین.<br />&trade; إذا تناوُلت كمیة أكثر مما یجب من سیتافیك<br />إذا تناولت جرعة أكثر من الجرعة الموصوفة لك من ھذا الدواء، فاتصل بالطبیب المعالج لك<br />فورًا. توجّھ إلى المستشفى إذا كنت تعاني من أعراض الحُماض اللاكتیكي مثل شعور بالبرد أو<br />عدم الراحة أو غثیان أو قيء شدید أو ألم بالمعدة أو فقدان غیر مبرر للوزن أو تشنج بالعضلات<br />أو سرعة التنفس (انظر قسم &quot;تحذیرات واحتیاطات&quot;).<br />:&trade; إذا نسیت تناوُل سیتافیك<br />إذا نسیت تناوُل إحدى الجُرعات، فتناوُلھا بمُجرد تذكُّرك لھا. إذا لم تتذكرھا حتى حلول موعد<br />تناوُل جرعتك التالیة، فتجاوز الجرعة التي نسیتھا واستمر في تناوُل الجرعات بشكل منتظم وفقًا<br />لجدولك المعتاد. لا تتناول جرعة مضاعفة لتعویض جرعة أغفلتھا.<br />:&trade; إذا توقفت عن تناول سیتافیك<br />للفترة التي یصفھا الطبیب المعالج لك حتى تستمر في &trade; ینبغي الاستمرار في تناوُل سیتافیك<br />التحكم في مستوى السكر بالدم. یحظر التوقف عن تناوُل ھذا الدواء دون الرجوع إلى الطبیب<br />فقد یرتفع مستوى السكر في الدم مرة أخرى. ،&trade; المعالج لك أولًا. إذا توقفت عن تناول سیتافیك<br />إذا كانت لدیك أیّة أسئلة إضافیة أخرى حول تناول ھذا الدواء، فاستشر الطبیب المعالج لك أو<br />الصیدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr">قد یُسبب ھذا الدواء، مثلھ مثل كافة الأدویة، آثارًا جانبیة على الرغم من عدم حدوثھا لدى جمیع<br />المرضى.<br />واستشر الطبیب المعالج لك فورًا، إذا لاحظت أیًا من الآثار الجانبیة &trade; توقف عن تناوُل سیتافیك<br />الخطیرة التَّالیة:<br />&bull; ألم شدید ومستمر بالمعدة (منطقة البطن)، قد یمتد إلى الظھر سواء كان مصحوبًا بغثیان وقيء<br />أم لا، فقد تكون أعراض التھاب بالبنكریاس (التھابات البنكریاس).<br />آثارًا جانبیة نادرة جدًا (قد تؤثر على ما یصل إلى مریض واحد من بین كل &trade; یسبب سیتافیك<br />۱۰٫۰۰۰ مرضى)، ولكنھا خطیرة للغایة وتُعرف باسم الحماض اللاكتیكي<br />واتصل بالطبیب المعالج لك &trade; (انظر قسم &quot;تحذیرات واحتیاطات&quot;). توقف عن تناول سیتافیك<br />أو اذھب إلى أقرب مستشفى فورًا، إذا كنت تعرضت للإصابة بالحماض اللاكتیكي، حیث قد<br />تؤدي الإصابة بھ إلى حدوث غیبوبة.<br />إذا كنت تُعاني من تفاعلات حساسیة خطیرة (غیر معروف معدل تكرارھا) وتشتمل على: طفح<br />جلدي، شرى (ارتیكاریا)، بثور على البشرة/تقشر الجلد وتورُّم بالوجھ والشفاه واللسان والحلق<br />مما قد یسبب صعوبة في التنفس أو البلع، توقف عن تناوُل ھذا الدواء واتصل بالطبیب المعالج<br />لك على الفور.<br />قد یصف الطبیب المعالج لك دواءً لعلاج تفاعلات الحساسیة ودواء آخر لعلاج مرض السكري.<br />قد تعرض بعض المرضى الذین یتناولون میتفورمین للإصابة بالآثار الجانبیة التالیة بعد بدء<br />العلاج باستخدام سیتاجلبتین:<br />آثار جانبیة شائعة: (قد تُؤثر على ما یصل إلى مریض واحد من بین كل ۱۰ مرضى): انخفاض<br />نسبة السكر في الدم، غثیان، انتفاخ البطن، قيء.<br />آثار جانبیة غیر شائعة: (قد تُؤثر على ما یصل إلى مریض واحد من بین كل ۱۰۰ مریض):<br />ألم بالمعدة، إسھال، إمساك، شعور بالنُعاس.<br />تعرض بعض المرضى للإصابة بإسھال أو غثیان أو انتفاخ بالبطن أو إمساك أو ألم بالمعدة أو<br />قيء عند البدء في استخدام سیتاجلبتین بمصاحبة میتفورمین (معدل التكرار: شائع).<br />تعرض بعض المرضى للإصابة بالآثار الجانبیة التالیة أثناء تناولھم ھذا الدواء بمصاحبة أحد<br />أدویة مجموعة سلفونیل یوریا مثل جلیمیبیرید:<br />آثار جانبیة شائعة جدًا: (قد تُؤثر على أكثر من مریض واحد من بین كل ۱۰ مرضى):<br />انخفاض السكر في الدم.<br />آثار جانبیة شائعة: إمساك.<br />تعرض بعض المرضى للإصابة بالآثار الجانبیة التالیة أثناء تناولھم ھذا الدواء بمصاحبة<br />بیوجلیتازون.<br />آثار جانبیة شائعة: تورم بالیدین أو الساقین.<br />تعرض بعض المرضى للإصابة بالآثار الجانبیة التالیة أثناء تناولھم ھذا الدواء بمصاحبة<br />الأنسولین:<br />آثار جانبیة شائعة جدًا: انخفاض نسبة السكر في الدم.<br />آثار جانبیة غیر شائعة: جفاف الفم وصداع.<br />تعرض بعض المرضى للإصابة بالآثار الجانبیة التالیة أثناء إجراء الدراسات السریریة عند<br />أو أثناء تجارب ما قبل (&trade; تناوُل سیتاجلبتین بمفرده (أحد المواد الفعالة الموجودة في سیتافیك<br />أو مادة سیتاجلبتین سواءً بمفرده أو مع الأدویة الأخرى التي &trade; الموافقة على استخدام سیتافیك<br />تستخدم لعلاج مرض السُّكَّرِيّ:<br />آثار جانبیة شائعة: انخفاض نسبة السكر في الدم، صداع، عدوى بالجزء العلوي من الجھاز<br />التنفسي، انسداد الأنف أو سیلانھا والتھاب الحلق، ھشاشة العظام، ألم في الذراع أو الساق.<br />آثار جانبیة غیر شائعة: دوخة، إمساك، حكة.<br />آثار جانبیة نادرة: انخفاض عدد الصفائح الدمویة.<br />آثار جانبیة غیر معروف معدل تكرارھا: مشاكل بالكُلى (تتطلب في بعض الأحیان إجراء غسیل<br />كلوي)، قيء، آلام بالمفاصل، آلام بالعضلات، آلام بالظھر، مرض الرئة الخلالي، شَبیھُ الفُقَاع<br />(أحد أنواع بثور الجلد).<br />تعرض بعض المرضى للإصابة بالآثار الجانبیة التالیة عند تناول میتفورمین بمفرده:<br />آثار جانبیة شائعة جدًا: غثیان، قيء، إسھال، ألم بالمعدة، فقدان الشھیة. قد تحدث ھذه الآثار<br />الجانبیة عند بدء تناول میتفورمین ولكن عادة ما تزول.<br />آثار جانبیة شائعة: شعور بمذاق معدني بالفم.<br />آثار جانبیة نادرة جدًا: انخفاض مستویات فیتامین ب ۱۲ ، التھاب الكبد (مشكلة في الكبد)،<br />شرى، احمرار الجلد (طفح جلدي) أو حكة.<br />الإبلاغ عن الآثار الجانبیة<br />إذا تعرضت للإصابة بأي آثار جانبیة، فاستشر الطبیب المعالج لك أو الصیدلي الخاص بك أو<br />الممرض(ة) المتابع/(ة) لحالتك. ویشمل ذلك أیة آثار جانبیة مُحتمَلة غیر مُدرجة في ھذه النَّشرة.<br />یمكنك المساعدة في توفیر المزید من المعلومات حول أمان ھذا الدَّواء عن طریق الإبلاغ عن<br />الآثار الجانبیة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr">یُحفظ بعیدًا عن متناول ورؤیة الأطفال.<br />لا تستعمل ھذا الدَّواء بعد انتھاء تاریخ الصلاحیة المدون على الشریط والعبوة الكرتونیة بعد<br />.&quot;EXP&quot; كلمة<br />یُحفظ في درجة حرارة لا تزید عن ۳۰ درجة مئویة.<br />لا تتخلص من الأدویة عن طریق إلقائھا في میاه الصَّرف أو مع المخلفات المنزلیة.<br />استشر الصیدلي الخاص بك عن كیفیة التَّخلص من الأدویة التي لم تَعُد تستخدمھا. سوف تُساعد<br />ھذه الإجراءات في الحفاظ على البیئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr">ما ھي محتویات سیتافیك<br />- المواد الفعالة ھي سیتاجلبتین و میتفورمین.<br />٥۰ ملجم/ ۸٥۰ ملجم : یحتوي كل قرص مُغلَّف على ٥۰ ملجم سیتاجلبتین &trade; سیتافیك<br />(بما یعادل ٦٤,۲٥ ملجم من سیتاجلبتین فوسفات أحادي الھیدرات) و ۸٥۰ ملجم من<br />میتفورمین ھیدروكلوراید.<br />٥۰ ملجم/ ۱۰۰۰ ملجم : یحتوي كل قرص مُغلَّف على ٥۰ ملجم سیتاجلبتین &trade; سیتافیك<br />(بما یعادل ٦٤,۲٥ ملجم من سیتاجلبتین فوسفات أحادي الھیدرات) و ۱۰۰۰ ملجم من<br />میتفورمین ھیدروكلوراید.<br />- المكونات الأخرى ھى:<br />بولي فینیل بیرولیدون ، كبریتات لوریل الصودیوم ، سلیلوز دقیق التَّبلور ، فیومارات ستیریل<br />الصودیوم ، كحول بولي فینیل ، بولي إیثیلین جلایكول ، تلك ، ثاني أكسید التیتانیوم ، أكسید<br />الحدید الأحمر وأكسید الحدید الأسودقد لا تكون جمیع العبوات مسوقة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr" style="text-align:right">.<br />وما ھي محتویات العبوة؟ ؟&trade; ما ھو شكل سیتافیك<br />&#39;JP&#39; ٥۰ ملجم/ ۸٥۰ ملجم : أقراص مغلفة لونھا وردي، على شكل كبسولة محفور &trade; سیتافیك<br />على أحد جانبیھا و &rdquo; 206 &ldquo; على الجانب الآخر.<br />&#39;JP&#39; ٥۰ ملجم/ ۱۰۰۰ ملجم :أقراص مغلفة لونھا أحمر، على شكل كبسولة محفور &trade; سیتافیك<br />على أحد جانبیھا و &rdquo; 207 &ldquo; على الجانب الآخر.<br />٥۰ ملجم/ ۸٥۰ ملجم : في علبة تحتوي على ۸ شرائط في كل شریط &trade; تتوفر أقراص سیتافیك<br />۷ أقراص.<br />٥۰ ملجم/ ۱۰۰۰ ملجم : في علبة تحتوي على ۸ شرائط في كل &trade; تتوفر أقراص سیتافیك<br />شریط ۷ أقراص.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr">اسم وعنوان مالك رخصة التسویق و المصنع:<br />شركة مصنع جمجوم للأدویة،<br />جدة، منطقة مكة، المملكة العربیة السعودیة.<br />+۹٦٦-۱۲- ھاتف: ٦۰۸۱۱۱۱<br />+۹٦٦-۱۲- فاكس: ٦۰۸۱۲۲۲<br />www.jamjoompharma.com : الموقع الإلكتروني<br />للإبلاغ عن أي أثار جانبیھ:<br />&bull; المملكة العربیة السعودیة:<br />- المركز الوطني للتیقظ و السلامة الدوائیة<br />+۹٦٦-۱۱-۲۰٥- فاكس: ۷٦٦۲ o<br />للإتصال بالإدارة التنفیذیة للتیقظ وإدارة الأزمات. o<br />+۹٦٦-۱۱- ھاتف: ۲۰۳۸۲۲۲ o<br />2340-2356-2317 تحویلة</p><p dir="ltr">الخط الساخن للإبلاغ: ۱۹۹۹۹ o<br />npc.drug@sfda.gov.sa : برید إلكتروني o<br />www.sfda.gov.sa/npc : الموقع الإلكتروني o<br />&bull; دول الخلیج الأخرى:<br />- الرجاء الاتصال بالمؤسسات و الھیئات الوطنیة في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            09/2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sitavic (Sitagliptin/Metformin) 50mg/850mg Film Coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains sitagliptin phosphate monohydrate equivalent to 50 mg of sitagliptin and
850 mg of metformin hydrochloride.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film coated tablet.
Pink coloured, capsule shaped film coated tablets debossed with "JP" on one side and “206” on other
side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For adult patients with type 2 diabetes mellitus:<br />Sitavic is indicated as an adjunct to diet and exercise to improve glycaemic control in patients<br />inadequately controlled on their maximal tolerated dose of metformin alone or those already being<br />treated with the combination of sitagliptin and metformin.<br />Sitavic is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct<br />to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and<br />a sulphonylurea.<br />Sitavic is indicated as triple combination therapy with a peroxisome proliferator-activated receptor<br />gamma (PPAR&gamma;) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients<br />inadequately controlled on their maximal tolerated dose of metformin and a PPAR&gamma; agonist.<br />Sitavic is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and<br />exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do<br />not provide adequate glycaemic control.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The dose of antihyperglycaemic therapy with Sitavic should be individualized on the basis of the<br />patient&#39;s current regimen, effectiveness, and tolerability while not exceeding the maximum<br />recommended daily dose of 100 mg sitagliptin.<br />Adults with normal renal function (GFR &ge; 90 mL/min)<br />For patients inadequately controlled on maximal tolerated dose of metformin monotherapy<br />For patients not adequately controlled on metformin alone, the usual starting dose should provide<br />sitagliptin dosed as 50 mg twice daily (100 mg total daily dose) plus the dose of metformin already<br />being taken.</p><p>For patients switching from co-administration of sitagliptin and metformin<br />For patients switching from co-administration of sitagliptin and metformin, Sitavic should be initiated<br />at the dose of sitagliptin and metformin already being taken.<br />For patients inadequately controlled on dual combination therapy with the maximal tolerated dose of<br />metformin and a sulphonylurea<br />The dose should provide sitagliptin dosed as 50 mg twice daily (100 mg total daily dose) and a dose of<br />metformin similar to the dose already being taken. When Sitavic is used in combination with a<br />sulphonylurea, a lower dose of the sulphonylurea may be required to reduce the risk of hypoglycaemia<br />(see section 4.4).<br />For patients inadequately controlled on dual combination therapy with the maximal tolerated dose of<br />metformin and a PPAR&gamma; agonist<br />The dose should provide sitagliptin dosed as 50 mg twice daily (100 mg total daily dose) and a dose of<br />metformin similar to the dose already being taken.<br />For patients inadequately controlled on dual combination therapy with insulin and the maximal tolerated<br />dose of metformin<br />The dose should provide sitagliptin dosed as 50 mg twice daily (100 mg total daily dose) and a dose of<br />metformin similar to the dose already being taken. When Sitavic is used in combination with insulin, a<br />lower dose of insulin may be required to reduce the risk of hypoglycaemia (see section 4.4).<br />For the different doses on metformin, Sitavic is available in strengths of 50 mg sitagliptin and 850 mg<br />metformin hydrochloride or 1,000 mg metformin hydrochloride.<br />All patients should continue their recommended diet with an adequate distribution of carbohydrate<br />intake during the day.<br />Special populations<br />Renal impairment<br />No dose adjustment is needed for patients with mild renal impairment (glomerular filtration rate [GFR]<br />&ge; 60 mL/min). A GFR should be assessed before initiation of treatment with metformin-containing<br />products and at least annually thereafter. In patients at increased risk of further progression of renal<br />impairment and in the elderly, renal function should be assessed more frequently, e.g. every 3-6 months.<br />The maximum daily dose of metformin should preferably be divided into 2-3 daily doses. Factors that<br />may increase the risk of lactic acidosis (see section 4.4) should be reviewed before considering initiation<br />of metformin in patients with GFR &lt; 60 mL/min.<br />If no adequate strength of Sitavic is available, individual monocomponents should be used instead of<br />the fixed-dose combination<br />GFR mL/min Metformin Sitagliptin<br />60-89 Maximum daily dose is 3000 mg.<br />Dose reduction may be considered in<br />relation to declining renal function.<br />Maximum daily dose is 100 mg.<br />45-59 Maximum daily dose is 2000 mg.<br />The starting dose is at most half of the<br />maximum dose.<br />Maximum daily dose is 100 mg.<br />30-44 Maximum daily dose is 1000 mg. Maximum daily dose is 50 mg.</p><p>Hepatic impairment<br />Sitavic must not be used in patients with hepatic impairment (see section 5.2).<br />Elderly<br />As metformin and sitagliptin are excreted by the kidney, Sitavic should be used with caution as age<br />increases. Monitoring of renal function is necessary to aid in prevention of metformin-associated lactic<br />acidosis, particularly in the elderly (see sections 4.3 and 4.4).<br />Paediatric population<br />The safety and efficacy of Sitavic in children and adolescents from birth to &lt; 18 years of age have not<br />been established. No data are available.<br />Method of administration<br />Sitavic should be given twice daily with meals to reduce the gastrointestinal adverse reactions<br />associated with metformin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sitavic is contraindicated in patients with:
- hypersensitivity to the active substances or to any of the excipients listed in section 6.1 (see sections
4.4 and 4.8);
- any type of acute metabolic acidosis (such as lactic acidosis, diabetic ketoacidosis);
- diabetic pre-coma;
- severe renal failure (GFR< 30 mL/min) (see section 4.4);
- acute conditions with the potential to alter renal function such as:
- dehydration,
- severe infection,
- shock,
- intravascular administration of iodinated contrast agents (see section 4.4);
- acute or chronic disease which may cause tissue hypoxia such as:
- cardiac or respiratory failure,
- recent myocardial infarction,
- shock;
- hepatic impairment;
- acute alcohol intoxication, alcoholism;
- breast-feeding.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>General<br />Sitavic should not be used in patients with type 1 diabetes and must not be used for the treatment of<br />diabetic ketoacidosis.<br />Acute pancreatitis<br />Use of DPP-4 inhibitors has been associated with a risk of developing acute pancreatitis. Patients should<br />be informed of the characteristic symptom of acute pancreatitis: persistent, severe abdominal pain.<br />Resolution of pancreatitis has been observed after discontinuation of sitagliptin (with or without<br />supportive treatment), but very rare cases of necrotising or haemorrhagic pancreatitis and/or death have<br />been reported. If pancreatitis is suspected, Sitavic and other potentially suspect medicinal products<br />should be discontinued; if acute pancreatitis is confirmed, Sitavic should not be restarted. Caution<br />should be exercised in patients with a history of pancreatitis.<br />Lactic acidosis<br />Lactic acidosis, a rare but serious metabolic complication, most often occurs at acute worsening of renal<br />function or cardiorespiratory illness or sepsis. Metformin accumulation occurs at acute worsening of<br />renal function and increases the risk of lactic acidosis.<br />In case of dehydration (severe vomiting, diarrhoea, fever or reduced fluid intake), metformin should be<br />temporarily discontinued and contact with a health care professional is recommended.<br />Medicinal products that can acutely impair renal function (such as antihypertensives, diuretics and<br />NSAIDs) should be initiated with caution in metformin-treated patients. Other risk factors for lactic<br />acidosis are excessive alcohol intake, hepatic insufficiency, inadequately controlled diabetes, ketosis,<br />prolonged fasting and any conditions associated with hypoxia, as well as concomitant use of medicinal<br />products that may cause lactic acidosis (see sections 4.3 and 4.5).<br />Patients and/or care-givers should be informed of the risk of lactic acidosis. Lactic acidosis is<br />characterised by acidotic dyspnoea, abdominal pain, muscle cramps, asthenia and hypothermia followed<br />by coma. In case of suspected symptoms, the patient should stop taking metformin and seek immediate<br />medical attention. Diagnostic laboratory findings are decreased blood pH (&lt; 7.35), increased plasma<br />lactate levels (&gt; 5 mmol/L) and an increased anion gap and lactate/pyruvate ratio.<br />Renal function<br />GFR should be assessed before treatment initiation and regularly thereafter (see section 4.2). Sitavic is<br />contraindicated in patients with GFR &lt; 30 mL/min and should be temporarily discontinued during<br />conditions with the potential to alter renal function (see section 4.3).<br />Hypoglycaemia<br />Patients receiving Sitavic in combination with a sulphonylurea or with insulin may be at risk for<br />hypoglycaemia. Therefore, a reduction in the dose of the sulphonylurea or insulin may be necessary.<br />Hypersensitivity reactions<br />Post-marketing reports of serious hypersensitivity reactions in patients treated with sitagliptin have been<br />reported. These reactions include anaphylaxis, angioedema, and exfoliative skin conditions including<br />Stevens-Johnson syndrome. Onset of these reactions occurred within the first 3 months after initiation of<br />treatment with sitagliptin, with some reports occurring after the first dose. If a hypersensitivity reaction&nbsp;is suspected, Sitavic should be discontinued, other potential causes of the event should be assessed, and<br />alternative treatment for diabetes should be instituted (see section 4.8).<br />Bullous pemphigoid<br />There have been post-marketing reports of bullous pemphigoid in patients taking DPP-4 inhibitors<br />including sitagliptin. If bullous pemphigoid is suspected, Sitavic should be discontinued.<br />Surgery<br />Sitavic must be discontinued at the time of surgery under general, spinal or epidural anaesthesia.<br />Therapy may be restarted no earlier than 48 hours following surgery or resumption of oral nutrition and<br />provided that renal function has been re-evaluated and found to be stable.<br />Administration of iodinated contrast agent<br />Intravascular administration of iodinated contrast agents may lead to contrast-induced nephropathy,<br />resulting in metformin accumulation and an increased risk of lactic acidosis. Sitavic should be<br />discontinued prior to or at the time of the imaging procedure and not restarted until at least 48 hours<br />after, provided that renal function has been re-evaluated and found to be stable (see sections 4.3 and<br />4.5).<br />Change in clinical status of patients with previously controlled type 2 diabetes<br />A patient with type 2 diabetes previously well controlled on Sitavic who develops laboratory<br />abnormalities or clinical illness (especially vague and poorly defined illness) should be evaluated<br />promptly for evidence of ketoacidosis or lactic acidosis. Evaluation should include serum electrolytes<br />and ketones, blood glucose and, if indicated, blood pH, lactate, pyruvate, and metformin levels. If<br />acidosis of either form occurs, treatment must be stopped immediately and other appropriate corrective<br />measures initiated.<br />Sodium<br />This medicinal product contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially<br />&#39;sodium-free&#39;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Co-administration of multiple doses of sitagliptin (50 mg twice daily) and metformin (1,000 mg twice<br />daily) did not meaningfully alter the pharmacokinetics of either sitagliptin or metformin in patients with<br />type 2 diabetes.<br />Pharmacokinetic drug interaction studies with Sitavic have not been performed; however, such studies<br />have been conducted with the individual active substances, sitagliptin and metformin.<br />Concomitant use not recommended<br />Alcohol<br />Alcohol intoxication is associated with an increased risk of lactic acidosis, particularly in cases of<br />fasting, malnutrition or hepatic impairment.<br />Iodinated contrast agents<br />Sitavic must be discontinued prior to or at the time of the imaging procedure and not restarted until at<br />least 48 hours after, provided that renal function has been re-evaluated and found to be stable (see<br />sections 4.3 and 4.4).</p><p>Combinations requiring precautions for use<br />Some medicinal products can adversely affect renal function, which may increase the risk of lactic<br />acidosis, e.g. NSAIDs, including selective cyclo-oxygenase (COX) II inhibitors, ACE inhibitors,<br />angiotensin II receptor antagonists and diuretics, especially loop diuretics. When starting or using such<br />products in combination with metformin, close monitoring of renal function is necessary.<br />Concomitant use of drugs that interfere with common renal tubular transport systems involved in the<br />renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin<br />extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could<br />increase systemic exposure to metformin and may increase the risk for lactic acidosis. Consider the<br />benefits and risks of concomitant use. Close monitoring of glycaemic control, dose adjustment within<br />the recommended posology and changes in diabetic treatment should be considered when such products<br />are co administered.<br />Glucocorticoids (given by systemic and local routes) beta-2-agonists, and diuretics have intrinsic<br />hyperglycaemic activity. The patient should be informed and more frequent blood glucose monitoring<br />performed, especially at the beginning of treatment with such medicinal products. If necessary, the dose<br />of the anti-hyperglycaemic medicinal product should be adjusted during therapy with the other<br />medicinal product and on its discontinuation.<br />ACE-inhibitors may decrease the blood glucose levels. If necessary, the dose of the anti-hyperglycaemic<br />medicinal product should be adjusted during therapy with the other medicinal product and on its<br />discontinuation.<br />Effects of other medicinal products on sitagliptin<br />In vitro and clinical data described below suggest that the risk for clinically meaningful interactions<br />following co-administration of other medicinal products is low.<br />In vitro studies indicated that the primary enzyme responsible for the limited metabolism of sitagliptin is<br />CYP3A4, with contribution from CYP2C8. In patients with normal renal function, metabolism,<br />including via CYP3A4, plays only a small role in the clearance of sitagliptin. Metabolism may play a<br />more significant role in the elimination of sitagliptin in the setting of severe renal impairment or endstage<br />renal disease (ESRD). For this reason, it is possible that potent CYP3A4 inhibitors (i.e.,<br />ketoconazole, itraconazole, ritonavir, clarithromycin) could alter the pharmacokinetics of sitagliptin in<br />patients with severe renal impairment or ESRD. The effects of potent CYP3A4 inhibitors in the setting<br />of renal impairment have not been assessed in a clinical study.<br />In vitro transport studies showed that sitagliptin is a substrate for p-glycoprotein and organic anion<br />transporter-3 (OAT3). OAT3 mediated transport of sitagliptin was inhibited in vitro by probenecid,<br />although the risk of clinically meaningful interactions is considered to be low. Concomitant<br />administration of OAT3 inhibitors has not been evaluated in vivo.<br />Ciclosporin: A study was conducted to assess the effect of ciclosporin, a potent inhibitor of pglycoprotein,<br />on the pharmacokinetics of sitagliptin. Co-administration of a single 100 mg oral dose of<br />sitagliptin and a single 600 mg oral dose of ciclosporin increased the AUC and Cmax of sitagliptin by<br />approximately 29 % and 68 %, respectively. These changes in sitagliptin pharmacokinetics were not<br />considered to be clinically meaningful. The renal clearance of sitagliptin was not meaningfully altered.<br />Therefore, meaningful interactions would not be expected with other p-glycoprotein inhibitors.<br />Effects of sitagliptin on other medicinal products<br />Digoxin: Sitagliptin had a small effect on plasma digoxin concentrations. Following administration of<br />0.25 mg digoxin concomitantly with 100 mg of sitagliptin daily for 10 days, the plasma AUC of digoxin&nbsp;was increased on average by 11 %, and the plasma Cmax on average by 18 %. No dose adjustment of<br />digoxin is recommended. However, patients at risk of digoxin toxicity should be monitored for this<br />when sitagliptin and digoxin are administered concomitantly.<br />In vitro data suggest that sitagliptin does not inhibit nor induce CYP450 isoenzymes. In clinical studies,<br />sitagliptin did not meaningfully alter the pharmacokinetics of metformin, glyburide, simvastatin,<br />rosiglitazone, warfarin, or oral contraceptives, providing in vivo evidence of a low propensity for<br />causing interactions with substrates of CYP3A4, CYP2C8, CYP2C9, and organic cationic transporter<br />(OCT). Sitagliptin may be a mild inhibitor of p-glycoprotein in vivo.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />There are no adequate data from the use of sitagliptin in pregnant women. Studies in animals have<br />shown reproductive toxicity at high doses of sitagliptin (see section 5.3).<br />A limited amount of data suggests the use of metformin in pregnant women is not associated with an<br />increased risk of congenital malformations. Animal studies with metformin do not indicate harmful<br />effects with respect to pregnancy, embryonic or foetal development, parturition or postnatal<br />development (see also section 5.3).<br />Sitavic should not be used during pregnancy. If a patient wishes to become pregnant or if a pregnancy<br />occurs, treatment should be discontinued and the patient switched to insulin treatment as soon as<br />possible.<br />Breast-feeding<br />No studies in lactating animals have been conducted with the combined active substances of this<br />medicinal product. In studies performed with the individual active substances, both sitagliptin and<br />metformin are excreted in the milk of lactating rats. Metformin is excreted in human milk in small<br />amounts. It is not known whether sitagliptin is excreted in human milk. Sitavic must therefore not be<br />used in women who are breast-feeding (see section 4.3).<br />Fertility<br />Animal data do not suggest an effect of treatment with sitagliptin on male and female fertility. Human<br />data are lacking.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sitavic has no or negligible influence on the ability to drive and use machines. However, when driving<br />or using machines, it should be taken into account that dizziness and somnolence have been reported<br />with sitagliptin.<br />In addition, patients should be alerted to the risk of hypoglycaemia when Sitavic is used in combination<br />with a sulphonylurea or with insulin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />There have been no therapeutic clinical trials conducted with Sitavic tablets however bioequivalence of<br />Sitavic with co-administered sitagliptin and metformin has been demonstrated (see section 5.2). Serious&nbsp;adverse reactions including pancreatitis and hypersensitivity reactions have been reported.<br />Hypoglycaemia has been reported in combination with sulphonylurea (13.8%) and insulin (10.9%).<br />Sitagliptin and metformin<br />Tabulated list of adverse reactions<br />Adverse reactions are listed below as MedDRA preferred term by system organ class and absolute<br />frequency (Table 1). Frequencies are defined as: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10);<br />uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000) and not known<br />(cannot be estimated from the available data).<br />Table 1: The frequency of adverse reactions identified from placebo-controlled clinical studies of<br />sitagliptin and metformin alone, and post-marketing experience<br />Adverse reaction Frequency of adverse reaction<br />Blood and lymphatic system disorders<br />thrombocytopenia Rare<br />Immune system disorders<br />hypersensitivity reactions including anaphylactic<br />responses*,&dagger;<br />Frequency not known<br />Metabolism and nutrition disorders<br />hypoglycaemia&dagger; Common<br />Nervous system disorders<br />somnolence Uncommon<br />Respiratory, thoracic and mediastinal disorders<br />interstitial lung disease* Frequency not known<br />Gastrointestinal disorders<br />diarrhoea Uncommon<br />nausea Common<br />flatulence Common<br />constipation Uncommon<br />upper abdominal pain Uncommon<br />vomiting Common<br />acute pancreatitis*,&dagger;,&Dagger; Frequency not known<br />fatal and non-fatal haemorrhagic and necrotizing<br />pancreatitis*,&dagger;<br />Frequency not known<br />Skin and subcutaneous tissue disorders<br />pruritus* Uncommon<br />angioedema*,&dagger; Frequency not known<br />rash*,&dagger; Frequency not known<br />urticaria*,&dagger; Frequency not known<br />cutaneous vasculitis*,&dagger; Frequency not known<br />exfoliative skin conditions including Stevens-Johnson<br />syndrome*,&dagger; Frequency not known</p><p>bullous pemphigoid* Frequency not known<br />Musculoskeletal and connective tissue disorders<br />arthralgia* Frequency not known<br />myalgia* Frequency not known<br />pain in extremity* Frequency not known<br />back pain* Frequency not known<br />arthropathy* Frequency not known<br />Renal and urinary disorders<br />impaired renal function* Frequency not known<br />acute renal failure* Frequency not known<br />*Adverse reactions were identified through post-marketing surveillance.<br />&dagger; See section 4.4.<br />&Dagger; See TECOS Cardiovascular Safety Study below.<br />Description of selected adverse reactions<br />Some adverse reactions were observed more frequently in studies of combination use of sitagliptin and<br />metformin with other anti-diabetic medicinal products than in studies of sitagliptin and metformin alone.<br />These included hypoglycaemia (frequency very common with sulphonylurea or insulin), constipation<br />(common with sulphonylurea), peripheral oedema (common with pioglitazone), and headache and dry<br />mouth (uncommon with insulin).<br />Sitagliptin<br />In monotherapy studies of sitagliptin 100 mg once daily alone compared to placebo, adverse reactions<br />reported were headache, hypoglycaemia, constipation, and dizziness.<br />Among these patients, adverse events reported regardless of causal relationship to medicinal product<br />occurring in at least 5 % included upper respiratory tract infection and nasopharyngitis. In addition,<br />osteoarthritis and pain in extremity were reported with frequency uncommon (&gt; 0.5 % higher among<br />sitagliptin users than that in the control group).<br />Metformin<br />Gastrointestinal symptoms were reported very commonly in clinical studies and post-marketing use of<br />metformin. Gastrointestinal symptoms such as nausea, vomiting, diarrhoea, abdominal pain and loss of<br />appetite occur most frequently during initiation of therapy and resolve spontaneously in most cases.<br />Additional adverse reactions associated with metformin include metallic taste (common); lactic acidosis,<br />liver function disorders, hepatitis, urticaria, erythema, and pruritus (very rare). Long-term treatment with<br />metformin has been associated with a decrease in vitamin B12 absorption which may very rarely result<br />in clinically significant vitamin B12 deficiency (e.g., megaloblastic anaemia). Frequency categories are<br />based on information available from metformin Summary of Product Characteristics available in the EU.<br />TECOS Cardiovascular Safety Study<br />The Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) included 7,332 patients treated<br />with sitagliptin, 100 mg daily (or 50 mg daily if the baseline eGFR was &ge; 30 and &lt; 50 mL/min/1.73 m2),<br />and 7,339 patients treated with placebo in the intention-to-treat population. Both treatments were added<br />to usual care targeting regional standards for HbA1c and CV risk factors. The overall incidence of<br />serious adverse events in patients receiving sitagliptin was similar to that in patients receiving placebo.</p><p>In the intention-to-treat population, among patients who were using insulin and/or a sulfonylurea at<br />baseline, the incidence of severe hypoglycaemia was 2.7 % in sitagliptin-treated patients and 2.5 % in<br />placebo-treated patients; among patients who were not using insulin and/or a sulfonylurea at baseline,<br />the incidence of severe hypoglycaemia was 1.0 % in sitagliptin-treated patients and 0.7 % in placebotreated<br />patients. The incidence of adjudication-confirmed pancreatitis events was 0.3 % in sitagliptintreated<br />patients and 0.2 % in placebo-treated patients.<br />Reporting of suspected adverse reactions<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222,<br />Ext: 2317-2356-2340.<br />Reporting hotline: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>During controlled clinical trials in healthy subjects, single doses of up to 800 mg sitagliptin were<br />administered. Minimal increases in QTc, not considered to be clinically relevant, were observed in one<br />study at a dose of 800 mg sitagliptin. There is no experience with doses above 800 mg in clinical<br />studies. In Phase I multiple-dose studies, there were no dose-related clinical adverse reactions observed<br />with sitagliptin with doses of up to 600 mg per day for periods of up to 10 days and 400 mg per day for<br />periods of up to 28 days.<br />A large overdose of metformin (or co-existing risks of lactic acidosis) may lead to lactic acidosis which<br />is a medical emergency and must be treated in hospital. The most effective method to remove lactate and<br />metformin is haemodialysis.<br />In clinical studies, approximately 13.5 % of the dose was removed over a 3- to 4-hour haemodialysis<br />session. Prolonged haemodialysis may be considered if clinically appropriate. It is not known if<br />sitagliptin is dialysable by peritoneal dialysis.<br />In the event of an overdose, it is reasonable to employ the usual supportive measures, e.g., remove<br />unabsorbed material from the gastrointestinal tract, employ clinical monitoring (including obtaining an<br />electrocardiogram), and institute supportive therapy if required.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs used in diabetes, Combinations of oral blood glucose lowering drugs,<br />ATC code: A10BD07<br />Sitavic combines two antihyperglycaemic medicinal products with complementary mechanisms of<br />action to improve glycaemic control in patients with type 2 diabetes: sitagliptin phosphate, a dipeptidyl<br />peptidase 4 (DPP-4) inhibitor, and metformin hydrochloride, a member of the biguanide class.<br />Sitagliptin&nbsp;Mechanism of action<br />Sitagliptin phosphate is an orally-active, potent, and highly selective inhibitor of the dipeptidyl peptidase<br />4 (DPP-4) enzyme for the treatment of type 2 diabetes. The DPP-4 inhibitors are a class of agents that<br />act as incretin enhancers. By inhibiting the DPP-4 enzyme, sitagliptin increases the levels of two known<br />active incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic<br />polypeptide (GIP). The incretins are part of an endogenous system involved in the physiologic<br />regulation of glucose homeostasis. When blood glucose concentrations are normal or elevated, GLP-1<br />and GIP increase insulin synthesis and release from pancreatic beta cells. GLP-1 also lowers glucagon<br />secretion from pancreatic alpha cells, leading to reduced hepatic glucose production. When blood<br />glucose levels are low, insulin release is not enhanced and glucagon secretion is not suppressed.<br />Sitagliptin is a potent and highly selective inhibitor of the enzyme DPP-4 and does not inhibit the<br />closely-related enzymes DPP-8 or DPP-9 at therapeutic concentrations. Sitagliptin differs in chemical<br />structure and pharmacological action from GLP-1 analogues, insulin, sulphonylureas or meglitinides,<br />biguanides, peroxisome proliferator-activated receptor gamma (PPAR&gamma;) agonists, alpha-glucosidase<br />inhibitors, and amylin analogues.<br />In a two-day study in healthy subjects, sitagliptin alone increased active GLP-1 concentrations, whereas<br />metformin alone increased active and total GLP-1 concentrations to similar extents. Co-administration<br />of sitagliptin and metformin had an additive effect on active GLP-1 concentrations. Sitagliptin, but not<br />metformin, increased active GIP concentrations.<br />Clinical efficacy and safety<br />Overall, sitagliptin improved glycaemic control when used as monotherapy or in combination treatment.<br />In clinical trials, sitagliptin as monotherapy improved glycaemic control with significant reductions in<br />haemoglobin A1c (HbA1c) and fasting and postprandial glucose. Reduction in fasting plasma glucose<br />(FPG) was observed at 3 weeks, the first time point at which FPG was measured. The observed<br />incidence of hypoglycaemia in patients treated with sitagliptin was similar to placebo. Body weight did<br />not increase from baseline with sitagliptin therapy. Improvements in surrogate markers of beta cell<br />function, including HOMA-&beta; (Homeostasis Model Assessment-&beta;), proinsulin to insulin ratio, and<br />measures of beta cell responsiveness from the frequently-sampled meal tolerance test were observed.<br />Studies of sitagliptin in combination with metformin<br />In a 24-week, placebo-controlled clinical study to evaluate the efficacy and safety of the addition of<br />sitagliptin 100 mg once daily to ongoing metformin, sitagliptin provided significant improvements in<br />glycaemic parameters compared with placebo. Change from baseline in body weight was similar for<br />patients treated with sitagliptin relative to placebo. In this study there was a similar incidence of<br />hypoglycaemia reported for patients treated with sitagliptin or placebo.<br />In a 24-week placebo-controlled factorial study of initial therapy, sitagliptin 50 mg twice daily in<br />combination with metformin (500 mg or 1,000 mg twice daily) provided significant improvements in<br />glycaemic parameters compared with either monotherapy. The decrease in body weight with the<br />combination of sitagliptin and metformin was similar to that observed with metformin alone or placebo;<br />there was no change from baseline for patients on sitagliptin alone. The incidence of hypoglycaemia was<br />similar across treatment groups.<br />Study of sitagliptin in combination with metformin and a sulphonylurea<br />A 24-week placebo-controlled study was designed to evaluate the efficacy and safety of sitagliptin (100<br />mg once daily) added to glimepiride (alone or in combination with metformin). The addition of<br />sitagliptin to glimepiride and metformin provided significant improvements in glycaemic parameters.</p><p>Patients treated with sitagliptin had a modest increase in body weight (+1.1 kg) compared to those given<br />placebo.<br />Study of sitagliptin in combination with metformin and a PPAR&gamma; agonist<br />A 26-week placebo-controlled study was designed to evaluate the efficacy and safety of sitagliptin (100<br />mg once daily) added to the combination of pioglitazone and metformin. The addition of sitagliptin to<br />pioglitazone and metformin provided significant improvements in glycaemic parameters. Change from<br />baseline in body weight was similar for patients treated with sitagliptin relative to placebo. The<br />incidence of hypoglycaemia was also similar in patients treated with sitagliptin or placebo.<br />Study of sitagliptin in combination with metformin and insulin<br />A 24-week placebo-controlled study was designed to evaluate the efficacy and safety of sitagliptin (100<br />mg once daily) added to insulin (at a stable dose for at least 10 weeks) with or without metformin (at<br />least 1,500 mg). In patients taking pre-mixed insulin, the mean daily dose was 70.9 U/day. In patients<br />taking non-pre-mixed (intermediate/long-acting) insulin, the mean daily dose was 44.3 U/day. Data from<br />the 73 % of patients who were taking metformin are presented in Table 2. The addition of sitagliptin to<br />insulin provided significant improvements in glycaemic parameters. There was no meaningful change<br />from baseline in body weight in either group.<br />Table 2: HbA1c results in placebo-controlled combination therapy studies of sitagliptin and<br />metformin*<br />Study<br />Mean baseline<br />HbA1c (%)<br />Mean change from<br />baseline HbA1c (%)<br />Placebo-corrected mean change<br />in HbA1c (%)<br />(95 % CI)<br />Sitagliptin 100 mg once daily<br />added to ongoing metformin<br />therapy%<br />(N=453)<br />8.0 -0.7&dagger; -0.7&dagger;,&Dagger;<br />(-0.8, -0.5)<br />Sitagliptin 100 mg once daily<br />added to ongoing glimepiride<br />+ metformin therapy%<br />(N=115)<br />8.3 -0.6&dagger; -0.9&dagger;,&Dagger;<br />(-1.1, -0.7)<br />Sitagliptin 100 mg once daily<br />added to ongoing<br />pioglitazone + metformin<br />therapy&para;<br />(N=152)<br />8.8 -1.2&dagger; -0.7&dagger;,&Dagger;<br />(-1.0, -0.5)<br />Sitagliptin 100 mg once daily<br />added to ongoing insulin +<br />metformin therapy %<br />(N=223)<br />8.7 -0.7&sect; -0.5&sect;,&Dagger;<br />(-0.7, -0.4)<br />Initial Therapy (twice<br />daily)%:<br />Sitagliptin 50 mg +<br />metformin 500 mg<br />(N=183)<br />8.8 -1.4&dagger; -1.6&dagger;,&Dagger;<br />(-1.8, -1.3)<br />Initial Therapy (twice<br />daily)%:<br />8.8 -1.9&dagger; -2.1&dagger;,&Dagger;<br />(-2.3, -1.8)</p><p>Sitagliptin 50 mg +<br />metformin 1,000 mg<br />(N=178)<br />* All Patients Treated Population (an intention-to-treat analysis).<br />&dagger; Least squares means adjusted for prior antihyperglycaemic therapy status and baseline value.<br />&Dagger; p&lt; 0.001 compared to placebo or placebo + combination treatment.<br />% HbA1c (%) at week 24.<br />&para; HbA1c (%) at week 26.<br />&sect; Least squares mean adjusted for insulin use at Visit 1 (pre-mixed vs. non-pre-mixed [intermediate- or<br />long-acting]), and baseline value.<br />In a 52-week study, comparing the efficacy and safety of the addition of sitagliptin 100 mg once daily or<br />glipizide (a sulphonylurea ) in patients with inadequate glycaemic control on metformin monotherapy,<br />sitagliptin was similar to glipizide in reducing HbA1c (-0.7 % mean change from baselines at week 52,<br />with baseline HbA1c of approximately 7.5 % in both groups). The mean glipizide dose used in the<br />comparator group was 10 mg per day with approximately 40 % of patients requiring a glipizide dose of<br />&le; 5 mg/day throughout the study. However, more patients in the sitagliptin group discontinued due to<br />lack of efficacy than in the glipizide group. Patients treated with sitagliptin exhibited a significant mean<br />decrease from baseline in body weight (-1.5 kg) compared to a significant weight gain in patients<br />administered glipizide (+1.1 kg). In this study, the proinsulin to insulin ratio, a marker of efficiency of<br />insulin synthesis and release, improved with sitagliptin and deteriorated with glipizide treatment. The<br />incidence of hypoglycaemia in the sitagliptin group (4.9 %) was significantly lower than that in the<br />glipizide group (32.0 %).<br />A 24-week placebo-controlled study involving 660 patients was designed to evaluate the insulin-sparing<br />efficacy and safety of sitagliptin (100 mg once daily) added to insulin glargine with or without<br />metformin (at least 1,500 mg) during intensification of insulin therapy. Among patients taking<br />metformin, baseline HbA1c was 8.70 % and baseline insulin dose was 37 IU/day. Patients were<br />instructed to titrate their insulin glargine dose based on fingerstick fasting glucose values. Among<br />patients taking metformin, at Week 24, the increase in daily insulin dose was 19 IU/day in patients<br />treated with sitagliptin and 24 IU/day in patients treated with placebo. The reduction in HbA1c for<br />patients treated with sitagliptin, metformin, and insulin was -1.35 % compared to -0.90 % for patients<br />treated with placebo, metformin, and insulin, a difference of -0.45 % [95 % CI: -0.62, -0.29]. The<br />incidence of hypoglycaemia was 24.9 % for patients treated with sitagliptin, metformin, and insulin and<br />37.8 % for patients treated with placebo, metformin, and insulin. The difference was mainly due to a<br />higher percentage of patients in the placebo group experiencing 3 or more episodes of hypoglycaemia<br />(9.1 vs. 19.8 %). There was no difference in the incidence of severe hypoglycaemia.<br />Metformin<br />Mechanism of action<br />Metformin is a biguanide with antihyperglycaemic effects, lowering both basal and postprandial plasma<br />glucose. It does not stimulate insulin secretion and therefore does not produce hypoglycaemia.<br />Metformin may act via three mechanisms:<br />- by reduction of hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis&nbsp;- in muscle, by modestly increasing insulin sensitivity, improving peripheral glucose uptake and<br />utilisation<br />- by delaying intestinal glucose absorption<br />Metformin stimulates intracellular glycogen synthesis by acting on glycogen synthase. Metformin<br />increases the transport capacity of specific types of membrane glucose transporters (GLUT-1 and<br />GLUT-4).<br />Clinical efficacy and safety<br />In humans, independently of its action on glycaemia, metformin has favourable effects on lipid<br />metabolism. This has been shown at therapeutic doses in controlled, medium-term or long-term clinical<br />studies: metformin reduces total cholesterol, LDLc and triglyceride levels.<br />The prospective randomised (UKPDS) study has established the long-term benefit of intensive blood<br />glucose control in type 2 diabetes. Analysis of the results for overweight patients treated with metformin<br />after failure of diet alone showed:<br />- a significant reduction of the absolute risk of any diabetes-related complication in the metformin group<br />(29.8 events/1,000 patient-years) versus diet alone (43.3 events/1,000 patient-years), p=0.0023, and<br />versus the combined sulphonylurea and insulin monotherapy groups (40.1 events/1,000 patient-years),<br />p=0.0034<br />- a significant reduction of the absolute risk of any diabetes-related mortality: metformin 7.5<br />events/1,000 patient-years, diet alone 12.7 events/1,000 patient-years, p=0.017<br />- a significant reduction of the absolute risk of overall mortality: metformin 13.5 events/1,000 patientyears<br />versus diet alone 20.6 events/1,000 patient-years, (p=0.011), and versus the combined<br />sulphonylurea and insulin monotherapy groups 18.9 events/1,000 patient-years (p=0.021)<br />- a significant reduction in the absolute risk of myocardial infarction: metformin 11 events/1,000 patientyears,<br />diet alone 18 events/1,000 patient-years, (p=0.01).<br />The TECOS was a randomised study in 14,671 patients in the intention-to-treat population with an<br />HbA1c of &ge; 6.5 to 8.0 % with established CV disease who received sitagliptin (7,332) 100 mg daily (or<br />50 mg daily if the baseline eGFR was &ge; 30 and &lt; 50 mL/min/1.73 m2) or placebo (7,339) added to usual<br />care targeting regional standards for HbA1c and CV risk factors. Patients with an eGFR &lt; 30<br />mL/min/1.73 m2 were not to be enrolled in the study. The study population included 2,004 patients &ge; 75<br />years of age and 3,324 patients with renal impairment (eGFR &lt; 60 mL/min/1.73 m2).<br />Over the course of the study, the overall estimated mean (SD) difference in HbA1c between the<br />sitagliptin and placebo groups was 0.29 % (0.01), 95 % CI (-0.32, -0.27); p &lt; 0.001.<br />The primary cardiovascular endpoint was a composite of the first occurrence of cardiovascular death,<br />nonfatal myocardial infarction, nonfatal stroke, or hospitalisation for unstable angina. Secondary<br />cardiovascular endpoints included the first occurrence of cardiovascular death, nonfatal myocardial<br />infarction, or nonfatal stroke; first occurrence of the individual components of the primary composite;<br />all-cause mortality; and hospital admissions for congestive heart failure.<br />After a median follow up of 3 years, sitagliptin, when added to usual care, did not increase the risk of<br />major adverse cardiovascular events or the risk of hospitalisation for heart failure compared to usual<br />care without sitagliptin in patients with type 2 diabetes (Table 3).<br />Table 3: Rates of Composite Cardiovascular Outcomes and Key Secondary Outcomes<br />Sitagliptin 100 mg Placebo Hazard Ratio p-value</p><p>Analysis in the Intention-to-Treat Population<br />Number of patients 7,332 7,339 0.98 (0.89&ndash;<br />1.08)<br />&lt;0.001<br />Primary Composite Endpoint<br />(Cardiovascular death, nonfatal<br />myocardial infarction, nonfatal<br />stroke, or hospitalisation for<br />unstable angina) 839 (11.4) 4.1 851 (11.6) 4.2<br />Secondary Composite Endpoint<br />(Cardiovascular death, nonfatal<br />myocardial infarction, or nonfatal<br />stroke) 745 (10.2) 3.6 746 (10.2) 3.6<br />0.99 (0.89&ndash;<br />1.10) &lt;0.001<br />Secondary Outcome<br />Cardiovascular death 380 (5.2) 1.7 366 (5.0) 1.7 1.03 (0.89-1.19) 0.711<br />All myocardial infarction (fatal<br />and non-fatal) 300 (4.1) 1.4 316 (4.3) 1.5<br />0.95 (0.81&ndash;<br />1.11) 0.487<br />All stroke (fatal and non-fatal)<br />178 (2.4) 0.8 183 (2.5) 0.9<br />0.97 (0.79&ndash;<br />1.19) 0.760<br />Hospitalisation for unstable<br />angina 116 (1.6) 0.5 129 (1.8) 0.6<br />0.90 (0.70&ndash;<br />1.16) 0.419<br />Death from any cause<br />547 (7.5) 2.5 537 (7.3) 2.5<br />1.01 (0.90&ndash;<br />1.14) 0.875<br />Hospitalisation for heart failure&Dagger;<br />228 (3.1) 1.1 229 (3.1) 1.1<br />1.00 (0.83&ndash;<br />1.20) 0.983<br />* Incidence rate per 100 patient-years is calculated as 100 &times; (total number of patients with &ge; 1 event<br />during eligible exposure period per total patient-years of follow-up).<br />&dagger; Based on a Cox model stratified by region. For composite endpoints, the p-values correspond to a test<br />of non-inferiority seeking to show that the hazard ratio is less than 1.3. For all other endpoints, the pvalues<br />correspond to a test of differences in hazard rates.<br />&Dagger; The analysis of hospitalisation for heart failure was adjusted for a history of heart failure at baseline.<br />Paediatric population<br />The European Medicines Agency has waived the obligation to submit the results of studies with Sitavic<br />in all subsets of the paediatric population in type 2 diabetes mellitus (see section 4.2 for information on<br />paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sitavic<br />A bioequivalence study in healthy subjects demonstrated that the Sitavic (sitagliptin/metformin<br />hydrochloride) combination tablets are bioequivalent to co-administration of sitagliptin phosphate and<br />metformin hydrochloride as individual tablets.</p><p>The following statements reflect the pharmacokinetic properties of the individual active substances of<br />Sitavic<br />Sitagliptin<br />Absorption<br />Following oral administration of a 100-mg dose to healthy subjects, sitagliptin was rapidly absorbed,<br />with peak plasma concentrations (median Tmax) occurring 1 to 4 hours post-dose, mean plasma AUC of<br />sitagliptin was 8.52 &mu;M&bull;hr, Cmax was 950 nM. The absolute bioavailability of sitagliptin is<br />approximately 87 %. Since co-administration of a high-fat meal with sitagliptin had no effect on the<br />pharmacokinetics, sitagliptin may be administered with or without food.<br />Plasma AUC of sitagliptin increased in a dose-proportional manner. Dose-proportionality was not<br />established for Cmax and C24hr (Cmax increased in a greater than dose-proportional manner and<br />C24hr increased in a less than dose-proportional manner).<br />Distribution<br />The mean volume of distribution at steady state following a single 100-mg intravenous dose of<br />sitagliptin to healthy subjects is approximately 198 litres. The fraction of sitagliptin reversibly bound to<br />plasma proteins is low (38 %).<br />Biotransformation<br />Sitagliptin is primarily eliminated unchanged in urine, and metabolism is a minor pathway.<br />Approximately 79 % of sitagliptin is excreted unchanged in the urine.<br />Following a [14C]sitagliptin oral dose, approximately 16 % of the radioactivity was excreted as<br />metabolites of sitagliptin. Six metabolites were detected at trace levels and are not expected to contribute<br />to the plasma DPP-4 inhibitory activity of sitagliptin. In vitro studies indicated that the primary enzyme<br />responsible for the limited metabolism of sitagliptin was CYP3A4, with contribution from CYP2C8.<br />In vitro data showed that sitagliptin is not an inhibitor of CYP isoenzymes CYP3A4, 2C8, 2C9, 2D6,<br />1A2, 2C19 or 2B6, and is not an inducer of CYP3A4 and CYP1A2.<br />Elimination<br />Following administration of an oral [14C]sitagliptin dose to healthy subjects, approximately 100 % of the<br />administered radioactivity was eliminated in faeces (13 %) or urine (87 %) within one week of dosing.<br />The apparent terminal t&frac12; following a 100-mg oral dose of sitagliptin was approximately 12.4 hours.<br />Sitagliptin accumulates only minimally with multiple doses. The renal clearance was approximately 350<br />mL/min.<br />Elimination of sitagliptin occurs primarily via renal excretion and involves active tubular secretion.<br />Sitagliptin is a substrate for human organic anion transporter-3 (hOAT-3), which may be involved in the<br />renal elimination of sitagliptin. The clinical relevance of hOAT-3 in sitagliptin transport has not been<br />established. Sitagliptin is also a substrate of p-glycoprotein, which may also be involved in mediating<br />the renal elimination of sitagliptin. However, ciclosporin, a p-glycoprotein inhibitor, did not reduce the<br />renal clearance of sitagliptin. Sitagliptin is not a substrate for OCT2 or OAT1 or PEPT1/2<br />transporters. In vitro, sitagliptin did not inhibit OAT3 (IC50=160 &mu;M) or p-glycoprotein (up to 250 &mu;M)<br />mediated transport at therapeutically relevant plasma concentrations. In a clinical study sitagliptin had a<br />small effect on plasma digoxin concentrations indicating that sitagliptin may be a mild inhibitor of pglycoprotein.</p><p>Characteristics in patients<br />The pharmacokinetics of sitagliptin were generally similar in healthy subjects and in patients with type 2<br />diabetes.<br />Renal impairment<br />A single-dose, open-label study was conducted to evaluate the pharmacokinetics of a reduced dose of<br />sitagliptin (50 mg) in patients with varying degrees of chronic renal impairment compared to normal<br />healthy control subjects. The study included patients with mild, moderate, and severe renal impairment,<br />as well as patients with ESRD on haemodialysis. In addition, the effects of renal impairment on<br />sitagliptin pharmacokinetics in patients with type 2 diabetes and mild, moderate, or severe renal<br />impairment (including ESRD) were assessed using population pharmacokinetic analyses.<br />Compared to normal healthy control subjects, plasma AUC of sitagliptin was increased by<br />approximately 1.2-fold and 1.6-fold in patients with mild renal impairment (GFR &ge; 60 to &lt; 90 mL/min)<br />and patients with moderate renal impairment (GFR &ge; 45 to &lt; 60 mL/min), respectively. Because<br />increases of this magnitude are not clinically relevant, dosage adjustment in these patients is not<br />necessary.<br />Plasma AUC of sitagliptin was increased approximately 2-fold in patients with moderate renal<br />impairment (GFR &ge; 30 to &lt; 45 mL/min), and approximately 4-fold in patients with severe renal<br />impairment (GFR &lt; 30 mL/min), including patients with ESRD on haemodialysis. Sitagliptin was<br />modestly removed by haemodialysis (13.5 % over a 3- to 4-hour haemodialysis session starting 4 hours<br />post-dose).<br />Hepatic impairment<br />No dose adjustment for sitagliptin is necessary for patients with mild or moderate hepatic impairment<br />(Child-Pugh score &le; 9). There is no clinical experience in patients with severe hepatic impairment<br />(Child-Pugh score &gt; 9). However, because sitagliptin is primarily renally eliminated, severe hepatic<br />impairment is not expected to affect the pharmacokinetics of sitagliptin.<br />Elderly<br />No dose adjustment is required based on age. Age did not have a clinically meaningful impact on the<br />pharmacokinetics of sitagliptin based on a population pharmacokinetic analysis of Phase I and Phase II<br />data. Elderly subjects (65 to 80 years) had approximately 19 % higher plasma concentrations of<br />sitagliptin compared to younger subjects.<br />Paediatric<br />No studies with sitagliptin have been performed in paediatric patients.<br />Other patient characteristics<br />No dose adjustment is necessary based on gender, race, or body mass index (BMI). These characteristics<br />had no clinically meaningful effect on the pharmacokinetics of sitagliptin based on a composite analysis<br />of Phase I pharmacokinetic data and on a population pharmacokinetic analysis of Phase I and Phase II<br />data.<br />Metformin<br />Absorption</p><p>After an oral dose of metformin, Tmax is reached in 2.5 h. Absolute bioavailability of a 500 mg<br />metformin tablet is approximately 50-60 % in healthy subjects. After an oral dose, the non-absorbed<br />fraction recovered in faeces was 20-30 %.<br />After oral administration, metformin absorption is saturable and incomplete. It is assumed that the<br />pharmacokinetics of metformin absorption is non-linear. At the usual metformin doses and dosing<br />schedules, steady state plasma concentrations are reached within 24-48 h and are generally less than 1<br />&mu;g/mL. In controlled clinical trials, maximum metformin plasma levels (Cmax) did not exceed 5 &mu;g/mL,<br />even at maximum doses.<br />Food decreases the extent and slightly delays the absorption of metformin. Following administration of a<br />dose of 850 mg, a 40 % lower plasma peak concentration, a 25 % decrease in AUC and a 35 min<br />prolongation of time to peak plasma concentration was observed. The clinical relevance of this decrease<br />is unknown.<br />Distribution<br />Plasma protein binding is negligible. Metformin partitions into erythrocytes. The blood peak is lower<br />than the plasma peak and appears at approximately the same time. The red blood cells most likely<br />represent a secondary compartment of distribution. The mean Vd ranged between 63 &ndash; 276 L.<br />Biotransformation<br />Metformin is excreted unchanged in the urine. No metabolites have been identified in humans.<br />Elimination<br />Renal clearance of metformin is &gt; 400 mL/min, indicating that metformin is eliminated by glomerular<br />filtration and tubular secretion. Following an oral dose, the apparent terminal elimination half-life is<br />approximately 6.5 h. When renal function is impaired, renal clearance is decreased in proportion to that<br />of creatinine and thus the elimination half-life is prolonged, leading to increased levels of metformin in<br />plasma.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No animal studies have been conducted with Sitavic<br />In 16-week studies in which dogs were treated with either metformin alone or a combination of<br />metformin and sitagliptin, no additional toxicity was observed from the combination. The NOEL in<br />these studies was observed at exposures to sitagliptin of approximately 6 times the human exposure and<br />to metformin of approximately 2.5 times the human exposure.<br />The following data are findings in studies performed with sitagliptin or metformin individually.<br />Sitagliptin<br />Renal and liver toxicity were observed in rodents at systemic exposure values 58 times the human<br />exposure level, while the no-effect level was found at 19 times the human exposure level. Incisor teeth<br />abnormalities were observed in rats at exposure levels 67 times the clinical exposure level; the no-effect<br />level for this finding was 58-fold based on the 14-week rat study. The relevance of these findings for<br />humans is unknown. Transient treatment-related physical signs, some of which suggest neural toxicity,<br />such as open-mouth breathing, salivation, white foamy emesis, ataxia, trembling, decreased activity,<br />and/or hunched posture were observed in dogs at exposure levels approximately 23 times the clinical<br />exposure level. In addition, very slight to slight skeletal muscle degeneration was also observed<br />histologically at doses resulting in systemic exposure levels of approximately 23 times the human&nbsp;exposure level. A no-effect level for these findings was found at an exposure 6-fold the clinical exposure<br />level.<br />Sitagliptin has not been demonstrated to be genotoxic in preclinical studies. Sitagliptin was not<br />carcinogenic in mice. In rats, there was an increased incidence of hepatic adenomas and carcinomas at<br />systemic exposure levels 58 times the human exposure level. Since hepatotoxicity has been shown to<br />correlate with induction of hepatic neoplasia in rats, this increased incidence of hepatic tumours in rats<br />was likely secondary to chronic hepatic toxicity at this high dose. Because of the high safety margin (19-<br />fold at this no-effect level), these neoplastic changes are not considered relevant for the situation in<br />humans.<br />No treatment related effects on fertility were observed in male and female rats given sitagliptin prior to<br />and throughout mating.<br />In a pre-/post-natal development study performed in rats sitagliptin showed no adverse effects.<br />Reproductive toxicity studies showed a slight treatment-related increased incidence of foetal rib<br />malformations (absent, hypoplastic and wavy ribs) in the offspring of rats at systemic exposure levels<br />more than 29 times the human exposure levels. Maternal toxicity was seen in rabbits at more than 29<br />times the human exposure levels. Because of the high safety margins, these findings do not suggest a<br />relevant risk for human reproduction. Sitagliptin is secreted in considerable amounts into the milk of<br />lactating rats (milk/plasma ratio: 4:1).<br />Metformin<br />Preclinical data for metformin reveal no special hazard for humans based on conventional studies of<br />safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to<br />reproduction.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Polyvinylpyrrolidone<br />Sodium Lauryl sulphate<br />Microcrystalline cellulose<br />Sodium Stearyl Fumarate<br />Iron Oxide Red<br />Opadry Pink II 85F240109<br />Purified Water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 Months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg; C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sitavic 50mg/ 850mg film coated tablets re available in a box of 8 blisters, 7 tablets per each blister</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Company
P.O. Box 6267
Jeddah 21442, Saudi Arabia.
Tel: 00966-12-6081111
Fax: 00966-12-6081222
E-mail: jpharma@jamjoompharma.com
Website: www.jamjoompharma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                October 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>